Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old

Journal:

Clinical Infectious Diseases

Published:

2026-01-21

DOI:

10.1093/cid/ciag026

Affiliations:

12

Authors:

28

Go to article

Institutions	Authors	Share
Pfizer, United States of America (USA)	12.000000 12.000000	0.43
Pfizer Ltd., United Kingdom (UK)	4.000000	0.14
BioNTech, Germany	3.000000	0.11
University of Texas Medical Branch (UTMB), United States of America (USA)	2.000000	0.07
The University of Iowa (UI), United States of America (USA)	1.000000	0.04
East-West Medical Research Institute, United States of America (USA)	1.000000	0.04
Clinical Neuroscience Solutions, Inc., United States of America (USA)	1.000000	0.04
Sundance Clinical Research, United States of America (USA)	1.000000	0.04
Accellacare, United States of America (USA)	1.000000	0.04
Indago Research, United States of America (USA)	1.000000	0.04
CNS Healthcare, United States of America (USA)	1.000000	0.04

Interested in Immunology?